Global Uterine Cancer Therapeutics & Diagnostics Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

The "Uterine Cancer Therapeutics & Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

The publisher brings years of research experience to the 9th edition of this report. The 388-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Global Uterine Cancer Therapeutics and Diagnostics Market to Reach US$27.7 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for Uterine Cancer Therapeutics and Diagnostics estimated at US$19.5 Billion in the year 2020, is projected to reach a revised size of US$27.7 Billion by 2027, growing at a CAGR of 5.1% over the period 2020-2027.

Uterine Sarcomas, one of the segments analyzed in the report, is projected to grow at a 3.9% CAGR to reach US$9.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Endometrial Carcinomas segment is readjusted to a revised 5.8% CAGR for the next 7-year period. This segment currently accounts for a 62.4% share of the global Uterine Cancer Therapeutics and Diagnostics market.

The U.S. Accounts for Over 28.8% of Global Market Size in 2020, While China is Forecast to Grow at a 8.5% CAGR for the Period of 2020-2027

The Uterine Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$5.6 Billion in the year 2020. The country currently accounts for a 28.79% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$5.1 Billion in the year 2027 trailing a CAGR of 8.6% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.9% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR while Rest of European market (as defined in the study) will reach US$5.1 Billion by the year 2027.

Competitors identified in this market include, among others:

• Abbott Laboratories, Inc.
• ARIAD Pharmaceuticals, Inc.
• Becton, Dickinson and Company
• F. Hoffmann-La Roche AG
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Impact of Covid-19 and a Looming Global Recession
• Global Competitor Market Shares
• Uterine Cancer Therapeutics & Diagnostics Competitor Market Share Scenario Worldwide (in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

• Total Companies Profiled: 56

For more information about this report visit https://www.researchandmarkets.com/r/wpavdw

View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005670/en/